Ultragenyx's bone disease drug fails late-stage trials
ReutersDec 29, 2025 1:33 PM
Dec 29 (Reuters) - Ultragenyx Pharmaceutical RARE.O said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
TradingKey 2025 Markets Recap & Outlook | Crude Oil Prices Collapse, Can Oil Prices Stage a Comeback in 2026?
In 2025, the crude oil market experienced significant volatility. After two peaks within the year, an overall downward trend emerged, with WTI and Brent crude prices falling by over 20% respectively. This significant volatility in crude oil prices was primarily event-driven, influenced by factors suTradingKey
11 hours ago
TradingKey 2025 Markets Recap & Outlook | Bitcoin Price Repeatedly Hits New Highs, 2026 Can BTC Write Another Legend?
Multiple tailwinds in 2025 propelled Bitcoin to new highs, but many of these positives have already been priced in. In 2026, Bitcoin faces challenges such as liquidity tightening, as well as regulatory and monetary policy uncertainties. Wall Street is divided on Bitcoin's future outlook, with targetTradingKey
Fri, Dec 26
TradingKey 2025 Markets Recap & Outlook | Global Central Banks 2026 amid Post‑Easing Recovery and Diverging Paths
TradingKey - In 2025, major global central banks will largely maintain an accommodative stance, but the policy pace will decelerate notably. As the easing cycle draws to a close, how will global monetary policy evolve?TradingKey
Thu, Dec 25
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Tradingkey
